{"id":"mirvetuximab-soravtansine-plus-bevacizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neuropathy (peripheral)"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3545132","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) that binds folate receptor alpha (FRA), which is highly expressed on ovarian and other cancers, and delivers a microtubule-disrupting agent (DM4) intracellularly. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF) that prevents tumor neovascularization. The combination leverages dual mechanisms: targeted cytotoxicity via FRA and anti-angiogenic activity via VEGF inhibition.","oneSentence":"Mirvetuximab soravtansine targets folate receptor alpha on cancer cells to deliver a cytotoxic payload, while bevacizumab blocks VEGF to inhibit tumor angiogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:30.923Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Platinum-resistant ovarian cancer (folate receptor alpha positive)"},{"name":"Recurrent ovarian cancer"}]},"trialDetails":[{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT06890338","phase":"PHASE2","title":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-21","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":140},{"nctId":"NCT05445778","phase":"PHASE3","title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-03-15","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":520},{"nctId":"NCT07059845","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-13","conditions":"Ovarian Cancer","enrollment":320},{"nctId":"NCT02606305","phase":"PHASE1, PHASE2","title":"Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"ImmunoGen, Inc.","startDate":"2016-03-02","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer","enrollment":264},{"nctId":"NCT03836157","phase":"PHASE2","title":"Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer","status":"WITHDRAWN","sponsor":"University of Oklahoma","startDate":"2019-05-31","conditions":"Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MIRV"],"phase":"phase_3","status":"active","brandName":"Mirvetuximab soravtansine plus Bevacizumab","genericName":"Mirvetuximab soravtansine plus Bevacizumab","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mirvetuximab soravtansine targets folate receptor alpha on cancer cells to deliver a cytotoxic payload, while bevacizumab blocks VEGF to inhibit tumor angiogenesis. Used for Platinum-resistant ovarian cancer (folate receptor alpha positive), Recurrent ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}